{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T02:07:59Z","timestamp":1777946879985,"version":"3.51.4"},"reference-count":108,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1053\/j.seminhematol.2021.02.006","type":"journal-article","created":{"date-parts":[[2021,3,6]],"date-time":"2021-03-06T17:45:10Z","timestamp":1615052710000},"page":"85-94","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Management of ALCL and other CD30+ peripheral T-cell lymphomas with a focus on Brentuximab vedotin"],"prefix":"10.1053","volume":"58","author":[{"given":"Imran","family":"Nizamuddin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Galvez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Pro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1053\/j.seminhematol.2021.02.006_bib0001","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"The Non-Hodgkin's Lymphoma Classification P. A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma","volume":"89","year":"1997","journal-title":"Blood"},{"issue":"20","key":"10.1053\/j.seminhematol.2021.02.006_bib0002","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.seminhematol.2021.02.006_bib0003","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1080\/10428190802455867","article-title":"Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States","volume":"49","author":"Abouyabis","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.1053\/j.seminhematol.2021.02.006_bib0004","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1200\/JCO.2015.63.5540","article-title":"Racial Patterns of Peripheral T-Cell Lymphoma Incidence and Survival in the United States","volume":"34","author":"Adams","year":"2016","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1053\/j.seminhematol.2021.02.006_bib0005","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1053\/j.seminhematol.2021.02.006_bib0006","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","article-title":"Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry","volume":"124","author":"Ellin","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2021.02.006_bib0007","first-page":"443","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA: Cancer J Clin"},{"issue":"10168","key":"10.1053\/j.seminhematol.2021.02.006_bib0008","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1053\/j.seminhematol.2021.02.006_bib0009","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2014-10-567461","article-title":"The biology and management of systemic anaplastic large cell lymphoma","volume":"126","author":"Hapgood","year":"2015","journal-title":"Blood"},{"issue":"19","key":"10.1053\/j.seminhematol.2021.02.006_bib0010","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2021.02.006_bib0011","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1128\/MCB.17.4.2312","article-title":"Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis","volume":"17","author":"Bischof","year":"1997","journal-title":"Mol Cell Biol"},{"issue":"8","key":"10.1053\/j.seminhematol.2021.02.006_bib0012","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1182\/blood-2009-02-204735","article-title":"The proteomic signature of NPM\/ALK reveals deregulation of multiple cellular pathways","volume":"114","author":"Lim","year":"2009","journal-title":"Blood"},{"issue":"15","key":"10.1053\/j.seminhematol.2021.02.006_bib0013","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1182\/blood-2013-04-497933","article-title":"PRDM1\/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma","volume":"122","author":"Boi","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2021.02.006_bib0014","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/j.1365-2141.2007.06924.x","article-title":"Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell lymphomas","volume":"140","author":"Salaverria","year":"2008","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1053\/j.seminhematol.2021.02.006_bib0015","doi-asserted-by":"crossref","first-page":"19","DOI":"10.5858\/2010-0507-RAR.1","article-title":"Anaplastic large cell lymphoma: twenty-five years of discovery","volume":"135","author":"Kinney","year":"2011","journal-title":"Arch Pathol Lab Med"},{"issue":"12","key":"10.1053\/j.seminhematol.2021.02.006_bib0016","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","article-title":"ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project","volume":"111","author":"Savage","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2021.02.006_bib0017","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/PAS.0000000000000500","article-title":"Morphologic Features of ALK-negative anaplastic large cell lymphomas with DUSP22 rearrangements","volume":"40","author":"King","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"9","key":"10.1053\/j.seminhematol.2021.02.006_bib0018","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1182\/blood-2014-04-571091","article-title":"ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes","volume":"124","author":"Parrilla Castellar","year":"2014","journal-title":"Blood"},{"issue":"19","key":"10.1053\/j.seminhematol.2021.02.006_bib0019","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1182\/blood-2013-11-536359","article-title":"Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma","volume":"123","author":"Iqbal","year":"2014","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2021.02.006_bib0020","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [see comments]","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2021.02.006_bib0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V85.1.1.bloodjournal8511","article-title":"CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy","volume":"85","author":"Falini","year":"1995","journal-title":"Blood"},{"issue":"10","key":"10.1053\/j.seminhematol.2021.02.006_bib0022","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.5858\/arpa.2014-0295-CC","article-title":"Anaplastic large cell lymphoma: features presenting diagnostic challenges","volume":"138","author":"Pletneva","year":"2014","journal-title":"Arch Pathol Lab Med"},{"issue":"19","key":"10.1053\/j.seminhematol.2021.02.006_bib0023","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1182\/blood-2014-07-584953","article-title":"Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels","volume":"124","author":"Bossard","year":"2014","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2021.02.006_bib0024","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.3324\/haematol.2012.081935","article-title":"CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features","volume":"98","author":"Bettina","year":"2013","journal-title":"Haematologica"},{"issue":"8","key":"10.1053\/j.seminhematol.2021.02.006_bib0025","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.3324\/haematol.2013.084913","article-title":"CD30 expression in peripheral T-cell lymphomas","volume":"98","author":"Sabattini","year":"2013","journal-title":"Haematologica"},{"issue":"9","key":"10.1053\/j.seminhematol.2021.02.006_bib0026","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1182\/blood-2016-08-692566","article-title":"Peripheral T-cell lymphoma, not otherwise specified","volume":"129","author":"Broccoli","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2021.02.006_bib0027","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/bjh.15258","article-title":"Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network","volume":"181","author":"Federico","year":"2018","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1053\/j.seminhematol.2021.02.006_bib0028","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/annonc\/mdh392","article-title":"Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification","volume":"15","author":"Savage","year":"2004","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1053\/j.seminhematol.2021.02.006_bib0029","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s00277-016-2696-9","article-title":"Clinical and prognostic differences between ALK-negative anaplastic large cell lymphoma and peripheral T cell lymphoma, not otherwise specified: a single institution experience","volume":"95","author":"Deng","year":"2016","journal-title":"Ann Hematol"},{"issue":"26","key":"10.1053\/j.seminhematol.2021.02.006_bib0030","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1182\/blood.2019001821","article-title":"Brentuximab vedotin in the treatment of CD30+ PTCL","volume":"134","author":"Barta","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2021.02.006_bib0031","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1182\/blood-2006-01-0394","article-title":"Phenotype of neoplastic cells in angioimmunoblastic T-cell lymphoma is consistent with activated follicular B helper T cells","volume":"108","author":"Krenacs","year":"2006","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2021.02.006_bib0032","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1182\/blood.V99.2.627","article-title":"Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10","volume":"99","author":"Attygalle","year":"2002","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2021.02.006_bib0033","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.3324\/haematol.2015.126300","article-title":"Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets","volume":"100","author":"de Leval","year":"2015","journal-title":"Haematologica"},{"issue":"4","key":"10.1053\/j.seminhematol.2021.02.006_bib0034","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.3324\/haematol.2016.158428","article-title":"Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin","volume":"102","author":"Dobay","year":"2017","journal-title":"Haematologica"},{"issue":"9","key":"10.1053\/j.seminhematol.2021.02.006_bib0035","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.1182\/blood-2007-08-105759","article-title":"Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials","volume":"111","author":"Mourad","year":"2008","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2021.02.006_bib0036","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1182\/blood-2013-10-531509","article-title":"A targeted mutational landscape of angioimmunoblastic T-cell lymphoma","volume":"123","author":"Odejide","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2021.02.006_bib0037","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1182\/blood-2011-02-335216","article-title":"Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project","volume":"118","author":"Delabie","year":"2011","journal-title":"Blood"},{"issue":"13","key":"10.1053\/j.seminhematol.2021.02.006_bib0038","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1182\/blood-2012-11-466839","article-title":"Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: a retrospective study by the EBMT","volume":"121","author":"Jantunen","year":"2013","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.seminhematol.2021.02.006_bib0039","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1182\/blood-2011-10-385559","article-title":"How I treat enteropathy-associated T-cell lymphoma","volume":"119","author":"Di Sabatino","year":"2012","journal-title":"Blood"},{"issue":"21","key":"10.1053\/j.seminhematol.2021.02.006_bib0040","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.1182\/blood.V122.21.4252.4252","article-title":"Enteropathy-associated T-cell lymphoma type I, but not refractory celiac disease, strongly expresses CD30 and might benefit from brentuximab vedotin","volume":"122","author":"Sibon","year":"2013","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.seminhematol.2021.02.006_bib0041","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1182\/blood.V77.11.2419.2419","article-title":"Detection and characterization of human T-cell lymphotropic virus type I (HTLV-I) associated T-cell neoplasms in an HTLV-I nonendemic region by polymerase chain reaction","volume":"77","author":"Chadburn","year":"1991","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2021.02.006_bib0042","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000431058","article-title":"Molecular pathology of adult T-cell leukemia\/lymphoma","volume":"89","author":"Ohshima","year":"2015","journal-title":"Oncology"},{"issue":"11","key":"10.1053\/j.seminhematol.2021.02.006_bib0043","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1182\/blood-2005-09-3801","article-title":"Identification of subtype-specific genomic alterations in aggressive adult T-cell leukemia\/lymphoma","volume":"107","author":"Oshiro","year":"2006","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2021.02.006_bib0044","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-2141.1991.tb08051.x","article-title":"Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87)","volume":"79","author":"Shimoyama","year":"1991","journal-title":"Br J Haematol"},{"issue":"24","key":"10.1053\/j.seminhematol.2021.02.006_bib0045","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1182\/blood-2015-03-632489","article-title":"Treatment and survival among 1594 patients with ATL","volume":"126","author":"Katsuya","year":"2015","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2021.02.006_bib0046","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/cncr.10480","article-title":"Adult T-cell leukemia\/lymphoma: a cytopathologic, immunocytochemical, and flow cytometric study","volume":"96","author":"Dahmoush","year":"2002","journal-title":"Cancer"},{"issue":"1","key":"10.1053\/j.seminhematol.2021.02.006_bib0047","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/hon.2900040109","article-title":"Virus associated adult T-cell leukemia (ATL) in Japan: clinical, histological and immunological studies","volume":"4","author":"Kikuchi","year":"1986","journal-title":"Hematol Oncol"},{"issue":"11","key":"10.1053\/j.seminhematol.2021.02.006_bib0048","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1038\/ng.3428","article-title":"The genomic landscape of adult T cell leukemia\/lymphoma","volume":"47","author":"Vicente","year":"2015","journal-title":"Nature Genetics"},{"issue":"10","key":"10.1053\/j.seminhematol.2021.02.006_bib0049","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/cncr.20999","article-title":"Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience","volume":"103","author":"Escal\u00f3n","year":"2005","journal-title":"Cancer"},{"issue":"2","key":"10.1053\/j.seminhematol.2021.02.006_bib0050","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-2141.2010.08329.x","article-title":"Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP\/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95","volume":"151","author":"Simon","year":"2010","journal-title":"Br J Haematol"},{"issue":"18","key":"10.1053\/j.seminhematol.2021.02.006_bib0051","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"issue":"19","key":"10.1053\/j.seminhematol.2021.02.006_bib0052","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1200\/JCO.2006.07.8972","article-title":"Phase I\/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma","volume":"25","author":"Ansell","year":"2007","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1053\/j.seminhematol.2021.02.006_bib0053","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood-2007-07-099317","article-title":"A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies","volume":"111","author":"Bartlett","year":"2008","journal-title":"Blood"},{"issue":"15_suppl","key":"10.1053\/j.seminhematol.2021.02.006_bib0054","doi-asserted-by":"crossref","first-page":"8531","DOI":"10.1200\/jco.2009.27.15_suppl.8531","article-title":"Phase I study of an anti-CD30 Fc engineered humanized monoclonal antibody in Hodgkin lymphoma (HL) or anaplastic large cell lymphoma (ALCL) patients: Safety, pharmacokinetics (PK), immunogenicity, and efficacy","volume":"27","author":"Blum","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9 Supplement","key":"10.1053\/j.seminhematol.2021.02.006_bib0055","first-page":"1227","article-title":"Abstract #1227: A phase I, open-label, dose-escalation, multidose study of MDX-1401 (defucosylated human antiCD30 monoclonal antibody) in patients with CD30-positive refractory\/relapsed Hodgkin\\#8217;s lymphoma","volume":"69","author":"Thertulien","year":"2009","journal-title":"Cancer Res"},{"issue":"6","key":"10.1053\/j.seminhematol.2021.02.006_bib0056","first-page":"1779","article-title":"A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma","volume":"8","author":"Schnell","year":"2002","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1053\/j.seminhematol.2021.02.006_bib0057","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","article-title":"cAC10-vcMMAE, an anti-CD30\u2013monomethyl auristatin E conjugate with potent and selective antitumor activity","volume":"102","author":"Francisco","year":"2003","journal-title":"Blood"},{"issue":"19","key":"10.1053\/j.seminhematol.2021.02.006_bib0058","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1053\/j.seminhematol.2021.02.006_bib0059","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1053\/j.seminhematol.2021.02.006_bib0060","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2017-05-780049","article-title":"Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma","volume":"130","author":"Pro","year":"2017","journal-title":"Blood"},{"issue":"20","key":"10.1053\/j.seminhematol.2021.02.006_bib0061","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"issue":"28","key":"10.1053\/j.seminhematol.2021.02.006_bib0062","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1200\/JCO.2013.54.2456","article-title":"Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study","volume":"32","author":"Fanale","year":"2014","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1053\/j.seminhematol.2021.02.006_bib0063","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1182\/blood-2017-12-821009","article-title":"Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas","volume":"131","author":"Fanale","year":"2018","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2021.02.006_bib0064","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1634\/theoncologist.2019-0098","article-title":"FDA approval summary: brentuximab vedotin in first-line treatment of peripheral T-Cell lymphoma","volume":"24","author":"Richardson","year":"2019","journal-title":"Oncologist"},{"issue":"Supplement_1","key":"10.1053\/j.seminhematol.2021.02.006_bib0065","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1182\/blood-2019-123166","article-title":"Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Positive Peripheral T-Cell Lymphomas","volume":"134","author":"Herrera","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2021.02.006_bib0066","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1158\/1078-0432.CCR-11-1425","article-title":"A phase I weekly dosing study of brentuximab vedotin in patients with relapsed\/refractory CD30-positive hematologic malignancies","volume":"18","author":"Fanale","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1053\/j.seminhematol.2021.02.006_bib0067","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1756-8722-7-24","article-title":"Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies","volume":"7","author":"Bartlett","year":"2014","journal-title":"J Hematol Oncol"},{"issue":"7","key":"10.1053\/j.seminhematol.2021.02.006_bib0068","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/cas.12435","article-title":"Phase I \/II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma","volume":"105","author":"Ogura","year":"2014","journal-title":"Cancer Sci"},{"issue":"3","key":"10.1053\/j.seminhematol.2021.02.006_bib0069","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/bcp.12988","article-title":"Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment","volume":"82","author":"Zhao","year":"2016","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1053\/j.seminhematol.2021.02.006_bib0070","doi-asserted-by":"crossref","first-page":"123","DOI":"10.6004\/jnccn.2018.0007","article-title":"NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018","volume":"16","author":"Horwitz","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"issue":"11","key":"10.1053\/j.seminhematol.2021.02.006_bib0071","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1016\/j.bbmt.2017.07.027","volume":"23","author":"Kharfan-Dabaja","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1053\/j.seminhematol.2021.02.006_bib0072","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1093\/annonc\/mdu443","article-title":"Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy","volume":"25","author":"Abramson","year":"2014","journal-title":"Annals of Oncology"},{"issue":"3","key":"10.1053\/j.seminhematol.2021.02.006_bib0073","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/annonc\/mdx787","article-title":"Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers","volume":"29","author":"Fossard","year":"2018","journal-title":"Ann Oncol"},{"issue":"25","key":"10.1053\/j.seminhematol.2021.02.006_bib0074","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"d'Amore","year":"2012","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1053\/j.seminhematol.2021.02.006_bib0075","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1038\/leu.2014.79","article-title":"Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma","volume":"28","author":"Corradini","year":"2014","journal-title":"Leukemia"},{"issue":"7","key":"10.1053\/j.seminhematol.2021.02.006_bib0076","doi-asserted-by":"crossref","first-page":"e452","DOI":"10.1038\/bcj.2016.63","article-title":"First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation","volume":"6","author":"Wilhelm","year":"2016","journal-title":"Blood Cancer J"},{"issue":"Supplement_1","key":"10.1053\/j.seminhematol.2021.02.006_bib0077","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1182\/blood-2019-122781","article-title":"An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Consolidative Stem Cell Transplant","volume":"134","author":"Savage","year":"2019","journal-title":"Blood"},{"issue":"15_suppl","key":"10.1053\/j.seminhematol.2021.02.006_bib0078","doi-asserted-by":"crossref","first-page":"7503","DOI":"10.1200\/JCO.2019.37.15_suppl.7503","article-title":"First-line therapy of T-cell lymphoma: allogeneic or autologous transplantation for consolidation\u2014Final results of the AATT study","volume":"37","author":"Shmitz","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2021.02.006_bib0079","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJM199807023390104","article-title":"Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma","volume":"339","author":"Miller","year":"1998","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1053\/j.seminhematol.2021.02.006_bib0080","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/ejh.12060","article-title":"Favorable outcome with doxorubicin-based chemotherapy and radiotherapy for adult patients with early stage primary systemic anaplastic large-cell lymphoma","volume":"90","author":"Zhang","year":"2013","journal-title":"Eur J Haematol"},{"issue":"21","key":"10.1053\/j.seminhematol.2021.02.006_bib0081","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.1200\/JCO.2005.09.098","article-title":"Treatment of refractory Hodgkin's lymphoma patients with an iodine-131\u2013labeled murine anti-CD30 monoclonal antibody","volume":"23","author":"Schnell","year":"2005","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1053\/j.seminhematol.2021.02.006_bib0082","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1182\/blood-2014-12-614636","article-title":"A phase 1 study of the bispecific anti-CD30\/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma","volume":"125","author":"Rothe","year":"2015","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2021.02.006_bib0083","doi-asserted-by":"crossref","first-page":"945","DOI":"10.3389\/fonc.2019.00945","article-title":"Development of a bispecific antibody targeting CD30 and CD137 on Hodgkin and Reed-Sternberg Cells","volume":"9","author":"Rajendran","year":"2019","journal-title":"Front Oncol"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2021.02.006_bib0084","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1182\/blood-2018-99-115269","article-title":"Clinical and Biological Evaluation of the Novel CD30\/CD16A Tetravalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma with Cutaneous Presentation: A Biomarker Phase Ib\/IIa Study (NCT03192202)","volume":"132","author":"Sawas","year":"2018","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2021.02.006_bib0085","unstructured":"Affimed. Affimed announces FDA granted orphan drug designation for lead innate cell engager AFM13 for the treatment of T-cell lymphoma; 2020."},{"issue":"15_suppl","key":"10.1053\/j.seminhematol.2021.02.006_bib0086","doi-asserted-by":"crossref","first-page":"TPS3148","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS3148","article-title":"A phase II open-label multicenter study to assess the efficacy and safety of AFM13 in patients with relapsed or refractory CD30-positive peripheral T-cell lymphoma or transformed mycosis fungoides: the REDIRECT study design and rationale","volume":"38","author":"Choe-Juliak","year":"2020","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2021.02.006_bib0087","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1182\/blood-2018-99-113534","article-title":"Clinical responses to CAR.CD30-T cells in patients with CD30+ lymphomas relapsed after multiple treatments including brentuximab vedotin","volume":"132","author":"Grover","year":"2018","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2021.02.006_bib0088","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.3324\/haematol.2017.186577","article-title":"The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project","volume":"103","author":"Bellei","year":"2018","journal-title":"Haematologica"},{"issue":"3","key":"10.1053\/j.seminhematol.2021.02.006_bib0089","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/hon.2144","article-title":"Dismal outcome of T-cell lymphoma patients failing first-line treatment: results of a population-based study from the Modena Cancer Registry","volume":"33","author":"Biasoli","year":"2015","journal-title":"Hematol Oncol"},{"issue":"16","key":"10.1053\/j.seminhematol.2021.02.006_bib0090","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors","volume":"31","author":"Mak","year":"2013","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1053\/j.seminhematol.2021.02.006_bib0091","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","article-title":"Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma","volume":"117","author":"Piekarz","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2021.02.006_bib0092","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Coiffier","year":"2012","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1053\/j.seminhematol.2021.02.006_bib0093","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study","volume":"33","author":"O'Connor","year":"2015","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1053\/j.seminhematol.2021.02.006_bib0094","doi-asserted-by":"crossref","first-page":"4921","DOI":"10.1158\/1078-0432.CCR-10-1214","article-title":"Folotyn (pralatrexate injection) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma: U.S. Food and Drug Administration drug approval summary","volume":"16","author":"Malik","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1053\/j.seminhematol.2021.02.006_bib0095","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O'Connor","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1053\/j.seminhematol.2021.02.006_bib0096","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2017-09-806737","article-title":"A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma","volume":"131","author":"Amengual","year":"2018","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2021.02.006_bib0097","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/ejh.13368","article-title":"Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30-positive aggressive lymphomas","volume":"104","author":"Wagner","year":"2020","journal-title":"Eur J Haematol"},{"issue":"2","key":"10.1053\/j.seminhematol.2021.02.006_bib0098","doi-asserted-by":"crossref","first-page":"djt378","DOI":"10.1093\/jnci\/djt378","article-title":"Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients","volume":"106","author":"Gambacorti Passerini","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"10.1053\/j.seminhematol.2021.02.006_bib0099","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.bbmt.2008.04.004","article-title":"Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience","volume":"14","author":"Chen","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1053\/j.seminhematol.2021.02.006_bib0100","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1093\/annonc\/mdg459","article-title":"High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience","volume":"14","author":"Rodr\u00edguez","year":"2003","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1053\/j.seminhematol.2021.02.006_bib0101","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00277-015-2309-z","article-title":"Modified ESHAP regimen for relapsed\/refractory T cell lymphoma: a retrospective analysis","volume":"94","author":"Kogure","year":"2015","journal-title":"Ann Hematol"},{"issue":"11","key":"10.1053\/j.seminhematol.2021.02.006_bib0102","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1007\/s00277-015-2468-y","article-title":"Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial","volume":"94","author":"Park","year":"2015","journal-title":"Ann Hematol"},{"issue":"10","key":"10.1053\/j.seminhematol.2021.02.006_bib0103","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1080\/10428194.2017.1312379","article-title":"Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study(","volume":"58","author":"Skamene","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1053\/j.seminhematol.2021.02.006_bib0104","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/ajh.25463","article-title":"Single agents vs combination chemotherapy in relapsed and refractory peripheral T-cell lymphoma: Results from the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) registry","volume":"94","author":"Stuver","year":"2019","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1053\/j.seminhematol.2021.02.006_bib0105","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1182\/blood-2009-06-227579","article-title":"Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma","volume":"115","author":"Iqbal","year":"2010","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1053\/j.seminhematol.2021.02.006_bib0106","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-123986","article-title":"A phase 2 study of the dual SYK\/JAK inhibitor cerdulatinib demonstrates good tolerability and clinical response in relapsed\/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma","volume":"134","author":"Horwitz","year":"2019","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2021.02.006_bib0107","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1016\/j.celrep.2019.10.083","article-title":"Targeting excessive EZH1 and EZH2 activities for abnormal histone methylation and transcription network in malignant lymphomas","volume":"29","author":"Yamagishi","year":"2019","journal-title":"Cell Rep"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2021.02.006_bib0108","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1182\/blood-2020-140412","article-title":"Duvelisib in patients with relapsed\/refractory peripheral T-cell lymphoma from the phase 2 primo trial: dose optimization efficacy update and expansion phase initial results","volume":"136","author":"Pro","year":"2020","journal-title":"Blood"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196321000160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196321000160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:28:03Z","timestamp":1758522483000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196321000160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":108,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0037196321000160"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2021.02.006","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of ALCL and other CD30+ peripheral T-cell lymphomas with a focus on Brentuximab vedotin","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2021.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}